Newsroom

RALEIGH, N.C.--(BUSINESS WIRE)--Digital.ai, which helps the world's most complex organizations deliver trusted software at AI speed, today announced the appointment of Craig Jones as Chief Revenue Officer. Jones will oversee Digital.ai's global revenue growth strategy, including sales, customer success, sales engineering, business development, and revenue operations. A multiple-time CRO, Jones brings more than 25 years of experience scaling enterprise commercial organizations across direct and...

SANTA CLARITA, Calif.--(BUSINESS WIRE)--Tombot’s Robotic Companion Jennie Makes Film Debut in “Walkies,” A Story of Healing & Connection...

PHILADELPHIA--(BUSINESS WIRE)--Seven private company boards have been honored with Private Company Boards of the Year awards for their business governance excellence by MLR Media. The awards will be presented at the 2026 Private Company Governance Summit®, which will take place June 10-12, 2026, at The Westin DC Downtown in Washington, D.C. The boards of these companies were selected for recognition: Benco Dental U.S. Venture Inc. Edmund Optics Wyo-Ben Inc. ThermFlo Inc./Zonatherm Products King...

PRINCETON, New Jersey, TOKYO e ZURIGO--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. e Araris Biotech AG ("Araris") oggi hanno annunciato il completamento del periodo di revisione relativo a un nuovo farmaco sperimentale (IND) da parte della U.S. Food and Drug Administration (FDA) su ARC-02, un anticorpo farmaco-coniugato (ADC) in corso di sviluppo per il trattamento dei linfomi non Hodgkin. Taiho Oncology può così dare inizio a uno studio clinico di fase 1 su ARC-02 con...

PRINCETON, Nueva Jersey; TOKIO; y ZÚRICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. y Araris Biotech AG (“Araris”) anunciaron hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha completado el período de revisión de un nuevo fármaco en investigación (IND) para ARC-02, un conjugado de anticuerpo y fármaco (ADC) en desarrollo para el tratamiento del linfoma no Hodgkin, lo que permite a Taiho Oncology iniciar un ensayo clínico de fase 1 con e...

PRINCETON, N.J. & TOKYO & ZÜRICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. en Araris Biotech AG ('Araris') hebben vandaag bekendgemaakt dat de Amerikaanse Food and Drug Administration (FDA) de beoordelingsperiode voor het Investigational New Drug (IND)-programma voor ARC-02, een antilichaam-geneesmiddelconjugaat (ADC) dat wordt ontwikkeld voor de behandeling van non-Hodgkin-lymfoom, heeft afgerond. Hiermee kan Taiho Oncology een Fase 1-dosisverhogingsstudie voor ARC...

PRINCETON, New Jersey & TOKIO & ZÜRICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., und Araris Biotech AG („Araris“) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) die Prüfungsphase für den Antrag auf Zulassung eines neuen Prüfpräparats (Investigational New Drug, IND) für ARC-02 abgeschlossen hat, ein Antikörper-Wirkstoff-Konjugat (ADC), das zur Behandlung von Non-Hodgkin-Lymphomen entwickelt wird. Damit kann Taih...

PRINCETON, New Jersey et TOKYO et ZURICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. et Araris Biotech AG (« Araris ») annoncent aujourd’hui que la Food and Drug Administration (FDA) des États-Unis a achevé la période d’examen de sa demande IND pour l'ARC-02, un conjugué anticorps-médicament (CAM) en développement pour le traitement du lymphome non hodgkinien, permettant à Taiho Oncology de lancer un essai clinique d’escalade de dose de phase 1 évaluant l'ARC-02. Taih...

CHATHAM, N.J.--(BUSINESS WIRE)--Bowker has announced a new partnership with Narrative Muse that will give its customers across the publishing ecosystem access to content discovery and audience intelligence services. Through the partnership, Bowker customers will be able to access Narrative Muse’s audience analysis and discovery services, helping authors and publishers better understand audience connection before release. “Authors and publishers are always looking for thoughtful ways to strength...

PHOENIX & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Forrester (Nasdaq: FORR) today launched the Forrester AI (formerly Izola) agent for Microsoft 365 Copilot, enabling clients to securely access trusted Forrester research and guidance directly within their daily workflows at no additional cost for existing license holders. This announcement follows Forrester’s recent Microsoft Teams integration, continuing to redefine how clients engage with research and advisory firms. In today’s fast‑moving, AI‑powe...